Athersys Reports First Quarter 2020 Results
Management to host conference call at 4:30 pm EDT today CLEVELAND–(BUSINESS WIRE)–$ATHX #ARDS–Athersys, Inc. (NASDAQ: ATHX) announced today its financial…
Pharmaceuticals, Biotechnology and Life Sciences
Management to host conference call at 4:30 pm EDT today CLEVELAND–(BUSINESS WIRE)–$ATHX #ARDS–Athersys, Inc. (NASDAQ: ATHX) announced today its financial…
LEXINGTON, Mass.–(BUSINESS WIRE)–Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi)…
— Management to Host Conference Call at 4:30 p.m. ET Today — MONROVIA, Calif.–(BUSINESS WIRE)–Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical…
Expected initiation of three new short-term zuranolone clinical studies in 2020, with the potential for three distinct indications April restructuring…
BLA for ROLONTIS® (eflapegrastim) under active FDA review – PDUFA date on October 24, 2020 ROLONTIS same day dosing study…
– Conference Call and Webcast Today, May 7 at 4:30 p.m. EDT PASADENA, Calif.–(BUSINESS WIRE)–$arwr–Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today…
Oligomerix, Inc., a privately held company focused on therapeutics targeting tau for Alzheimer’s disease similar dementias, which is also currently seeking strategic partners to support the acceleration and advancement of those programs, has appointed Robert Foerster as Chief Financial Officer.
Funding Enables Existing Clinical Trials to Proceed as Company Joins Global Response with COVID-19 Program PITTSBURGH–(BUSINESS WIRE)–Noveome Biotherapeutics, Inc., a…
LONDON–(BUSINESS WIRE)–#CompetitiveIntelligence–A well-known market intelligence company, Infiniti Research, has announced the completion of its latest article – Asian healthcare industry…
Schreiner MediPharm has developed a compact Booklet-Label for a needle protection system used in an international phase III clinical trial conducted by pharmaceutical corporation Sanofi.